- Pioneering Healthcare Future
Chronic Lymphocytic Leukemia (CLL): is a chronic, incurable disease, leading to great distress for patients and their families as well as huge costs for the health care system. Integrative analysis will be performed to address complex clinical questions and scenarios associating phenotypic data with personal genetic profiles derived from both conventional but also, critical to the mandate and objectives of AEGLE, high-throughput approaches.
In addition, AEGLE will offer the possibility of proposing and evaluating health interventions towards the goal of personalized medicine e.g. identifying groups with specific profiles that will be considered as eligible or ineligible for certain treatments and, at the same time, evaluating the cost of this intervention.
In an Intensive Care Unit (ICU) context, patient biosignals are continuously monitored and displayed towards recognizing alerting events. The recordings of clinical, laboratory data and physiologic waveforms could be analysed and displayed in an easy-tounderstand manner for clinicians.
AEGLE scalable data analytics will provide automated analysis of the fast changing multi-dimensional functions of variables for the detection of unusual, unstable or deteriorating states in patients. In this respect, early and personalized treatment will be feasible using AEGLE technology for higher survival in ICUs around European Hospitals.
The risk of developing T2D can be increased by various factors; usually a mixture of modifiable and non-modifiable elements of age, weight, genetics and ethnicity.
The AEGLE system will analyse the inter dependences of the factors including medication that are known to have a detrimental effect in type 2 diabetes to give a prediction on the potential deterioration. This would enable intervention to enable reduction of mortality, complications and hospitalization that would all lead to reduction in overall health costs.